Hypermarker clinical trial design finalised with patient input

The Hypermarker consortium is pleased to share a progress update on the development of its upcoming randomised clinical trial, a central component of the project’s mission to personalise hypertension care.

Over the past months, the clinical team has worked diligently to finalise the trial design, guided not only by scientific rigor but also by direct input from patients. Patient representatives played an active role in shaping key aspects of the study to ensure it reflects real-world needs, preferences, and lived experiences. 

The trial is set to take place across four countries, the United Kingdom, Netherlands, Spain, and Germany, enabling a broader and more diverse evaluation of the study objectives across healthcare settings.

This collaborative and inclusive approach reflects Hypermarker’s commitment to responsible, patient-centred innovation in clinical research.